Cargando…

OA04-06 LB. Post-infection cellular immune responses in recipients following ALVAC-HIV® + AIDSVAX® B/E prime-boost vaccination in the Thai Phase III Trial

Detalles Bibliográficos
Autores principales:	Kim, JH, Kamasuta, C, Trichavaroj, R, Kaewkungwal, J, Chantakulkij, S, Ratto-Kim, S, Eamsila, C, Sukwit, S, Nitayaphan, S, Pitsuttihum, P, Michael, NL, Chiu, J, Rerks-Ngarm, S, de Souza, MS, Paris, RM
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767552/ http://dx.doi.org/10.1186/1742-4690-6-S3-O30

Ejemplares similares

OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial
por: de Souza, MS, et al.
Publicado: (2009)

Identification of Immunodominant CD4-Restricted Epitopes Co-Located with Antibody Binding Sites in Individuals Vaccinated with ALVAC-HIV and AIDSVAX B/E
por: Ratto-Kim, Silvia, et al.
Publicado: (2015)

Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial
por: Zolla-Pazner, Susan, et al.
Publicado: (2013)

ALVAC-HIV and AIDSVAX B/E vaccination induce improved immune responses compared with AIDSVAX B/E vaccination alone
por: Costanzo, Margaret C., et al.
Publicado: (2023)

Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand
por: Pitisuttithum, Punnee, et al.
Publicado: (2011)

Ex Vivo Evaluation of Mucosal Responses to Vaccination with ALVAC and AIDSVAX of Non-Human Primates
por: Herrera, Carolina, et al.
Publicado: (2022)

P15-14. Assuring data quality of the phase III vaccine trial of ALVAC vaccine priming and AIDSVAX vaccine boosting in Thailand
por: Kaewkungwal, J, et al.
Publicado: (2009)

OA06-06 LB. Evidence of vaccine-induced changes in breakthrough HIV-1 strains from the Step trial
por: Rolland, M, et al.
Publicado: (2009)

Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency
por: Easterhoff, David, et al.
Publicado: (2020)

OA01-06 LB. HIV-1 plasma RNA and risk of HIV-1 transmission
por: Lingappa, JR, et al.
Publicado: (2009)

OA06-04. The role of early T-cell responses in subjects with acute HIV-1 infection
por: Liu, MK, et al.
Publicado: (2009)

P14-05. Recruitment, retention and participation impact events among women participating in phase III community trial in Thailand
por: Pitisuttithum, P, et al.
Publicado: (2009)

OA03-06 LB. Unique stimulatory properties of myeloid dendritic cells in individuals with "elite" HIV-1 control
por: Huang, J, et al.
Publicado: (2009)

P19-51 LB. Improvement of the efficacy of ALVAC-HIV vaccine candidates for humans in non human primates
por: Franchini, G
Publicado: (2009)

OA05-06 LB. First-in-human Phase 1 safety and immunigenicity of an adenovirus serotype 26 HIV-1 vaccine vector
por: Baden, LR, et al.
Publicado: (2009)

V1/V2-directed antibodies elicited in RV144 vaccinees bind to a structurally polymorphic site
por: McLellan, JS, et al.
Publicado: (2012)

OA01.04. Ayurvedic management of chronic rheumatoid arthritis with severe deformities - A case report
por: Sujithra, RM, et al.
Publicado: (2013)

Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene
por: O'Connell, RJ, et al.
Publicado: (2012)

Antibody responses to V2 loop are induced by CRF01_A E and not Clade B envelopes
por: Karasavvas, N, et al.
Publicado: (2012)

Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial preferentially use the VH1 gene family
por: Bonsignori, M, et al.
Publicado: (2012)

OA06.04. Dose-response of spinal manipulation for chronic low back pain: pain and disability outcomes from a randomized controlled trial
por: Haas, M, et al.
Publicado: (2012)

OA06.04 Immune Response after SARS-CoV-2 Vaccination in Lung Cancer Patients. Update of the Covid Lung Vaccine Cohort
por: Hernandez, A., et al.
Publicado: (2022)

S04-04 OA. HIV-specific responses induced by anti-CD40 targeting antibodies
por: Loof, N, et al.
Publicado: (2009)

OA04 Paediatric APS - children are not just small adults
por: Close, Rosie, et al.
Publicado: (2022)

OA02-06 LB. Recombinant modified Vaccinia virus ankara expressing HIV-1 genes activates NK subset capable of controlling HIN infection in vitro
por: Cummings, J, et al.
Publicado: (2009)

Genome Sequences of Erwinia Phyllophages AH04 and AH06
por: Krukonis, Greg P., et al.
Publicado: (2021)

OA01.06. A successful clinical case study of Asthenozoospermia + Oligozoospermia
por: Nadargi, Raghavendra
Publicado: (2013)

OA06 A complex case of thigh pain in Granulomatosis with Polyangiitis (GPA)
por: Ho, Gen Nen, et al.
Publicado: (2022)

S04-06 OA. Polyvalent Gag-specific CD8 T-cells with enhanced functional properties are enriched in HIV-1 clade C infected individuals with lower viral loads
por: Julg, B, et al.
Publicado: (2009)

Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand
por: Pitisuttithum, Punnee, et al.
Publicado: (2015)

OA16.04. Women’s sources of information for CAM use during pregnancy
por: Frawley, J, et al.
Publicado: (2012)

OA01.04. The effectiveness and cost effectiveness of acupressure for chemotherapy-related nausea
por: Hughes, J, et al.
Publicado: (2012)

OA02.04. Integrative Health Coaching: the accumulating research at Duke IM
por: Kosey, J, et al.
Publicado: (2012)

OA06 Behçet's associated myositis: an unusual cause of exercise-induced leg pain
por: Porter, Richard, et al.
Publicado: (2023)

Human Infection with Rickettsia honei, Thailand
por: Jiang, Ju, et al.
Publicado: (2005)

Gene profiling analysis of ALVAC infected human monocyte derived dendritic cells
por: Harenberg, Anke, et al.
Publicado: (2008)

OA03.04. To evaluate the effect of “Kadalikandadi kshara yoga” in the management of vataja ashmari”
por: Waddar, B Sujata, et al.
Publicado: (2013)

OA06.06 Impact of Systemic Anti-cancer Treatments on Outcomes of COVID-19 in Patients with Thoracic Cancers: CCC19 Registry Analysis
por: Kulkarni, A., et al.
Publicado: (2022)

OA06-03. Dynamics of CTL epitope escape and reversion in an African subtype C cohort
por: Schaefer, M, et al.
Publicado: (2009)

OA02.06. Importance of drug authentication and standardization as per API with the example of Alpinia species
por: Nini, KG, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7gda5tn83mlttmc0q5lllrpbkl